91 innovative vaccines in development by Vaccines Europe member companies 

December 1, 2025

Vaccines Europe published the fourth annual Pipeline Review today, 1st December 2025. The report provides an overview of the innovative preventive and therapeutic vaccines against infectious diseases, as well as prophylactic monoclonal antibodies (mAbs) currently in clinical development by Vaccines Europe member companies.  

41% of candidates target pathogens or diseases for which no vaccines or prophylactic mAbs have been registered, such as acne, Lyme disease, Epstein-Barr virus (EBV) infection and HIV. 

Highlights from the report include: 

  • 91 candidates in development, comprising 86 prophylactic and 2 therapeutic vaccines, as well as 3 prophylactic mAbs all targeting infectious agents. 
  • The candidates are developed using 12 distinct immunisation technologies, such as mRNA, protein-based vaccines, glycoconjugate vaccines and others. 
  • 46 candidates for routine immunisation, including human papillomavirus (HPV), measles, mumps, rubella, varicella (MMRV combination vaccine), meningococcal diseases and others. 
  • 68 candidates targeting respiratory-transmitted infections, including coronaviruses, influenza, respiratory syncytial virus (RSV), pneumococcal disease and others.  
  • 17 candidates targeting 8 bacteria associated with significant antibiotic resistance, 7 of which are on the World Health Organization Bacterial Priority Pathogens list: E. coli, P. aeruginosa, Salmonella spp., Shigella spp., S. aureus, Group B Streptococci and S. pneumoniae. 
  • 31 candidates are for infections originating from animals, including dengue fever, Lyme disease, Nipah virus, yellow fever and others. 

Sibilia Quilici, Executive Director of Vaccines Europe, said: “As immunisation research and development is advancing, Europe has a unique opportunity to lead. By investing boldly, embracing life-course immunisation, and setting the global standard for regulatory excellence, Europe can provide faster, broader protection to people and strengthen its role as a global leader in vaccines and life-science innovation.” 

The report illustrates how innovation in immunisation can help contribute to: 

  • Responding to demographic shifts and building resilient healthcare systems; 
  • Protecting travellers and communities against endemic diseases and local outbreaks; 
  • Protecting against or treating infection-associated cancers; 
  • Developing therapeutic vaccines against infectious agents; 
  • Combatting antimicrobial resistance (AMR) by slowing the emergence and spread of drug-resistant pathogens; 
  • Emergency preparedness. 

ENDS.